Q-omics provides the consensus-scored CAMTA1 profile across patient tissues and cancer cell-line models. CAMTA1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CAMTA1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CAMTA1 RNA expression shows 18,846 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where CAMTA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAMTA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAMTA1 survival associations across molecular data types. CAMTA1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAMTA1 RNA expression–survival associations across cancer types. High CAMTA1 expression shows unfavorable associations in ACC, LIHC, ESCA and UCEC, but favorable associations in LUAD and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CAMTA1 RNA expression.
This table summarizes CAMTA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CAMTA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAMTA1 shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in HNSC, LIHC and CHOL. The KICH box plot shows higher CAMTA1 RNA expression in normal versus tumor tissue (log2 FC = −1.084, t-test p < 0.001).
This table shows molecular features associated with CAMTA1 in patient tissues and cancer cell lines. In patient samples, CAMTA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAMTA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
